Physician profile
Kyle A Richards
NPI 1922200930
$3,517.90
in general payments reported to CMS, 2019-2025
20 companies · $45.94 in 2025
The $45.94 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $220 · 2021: $458 · 2022: $964 · 2023: $709 · 2024: $268 · 2025: $45.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $781.37 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $574.35 | 2019-2023 | Xarelto |
| Pfizer INC. | $484.92 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $269.55 | 2019-2023 | Camzyos |
| Amgen INC. | $241.29 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.03 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $156.68 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $151.98 | 2021-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $148.16 | 2019-2023 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $122.59 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.75 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $80.39 | 2019-2022 | |
| Lundbeck LLC | $50.75 | 2019 | |
| Novo Nordisk INC | $35.50 | 2023 | Ozempic, Rybelsus |
| Cardiva Medical, INC. | $26.47 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $19.80 | 2019 | |
| Tactile Systems Technology INC | $17.92 | 2022 | |
| Abbott Laboratories | $16.95 | 2019 | |
| Scpharmaceuticals INC. | $16.63 | 2023 | |
| Esperion Therapeutics, INC. | $15.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.